Logo

Genentech’s Lunsumio (mosunetuzumab-axgb) Receives the US FDA’s Approval for Relapsed or Refractory Follicular Lymphoma

Share this

Genentech’s Lunsumio (mosunetuzumab-axgb) Receives the US FDA’s Approval for Relapsed or Refractory Follicular Lymphoma

Shots:

  • The US FDA has approved Lunsumio (CD20xCD3 T-cell engaging bispecific Ab) for r/r FL after ≥2 lines of systemic therapy. The product can be administered as an IV inf. for a fixed duration & expected to be available in the US in the coming weeks
  • The approval was based on the P-II (GO29781) dose-escalation & expansion study evaluating Lunsumio in 836 patients with heavily pretreated FL who were at high risk of disease progression or whose disease was refractory to prior therapies
  • The results showed high & durable response rates, ORR (80%) with a majority of patients-maintained responses for 18mos, m-DoR was (22.8mos.), CR (60%). The effects of lunsumio on earlier line therapies for non-lymphoma Hodgkin's patients are being studied in P-III studies as an SC formulation

Ref: Businesswire | Image: Genentech

Related Posts:-  Genentech Reports the US FDA Acceptance of sBLA for Polivy (polatuzumab vedotin-piiq) to Treat Diffuse Large B-Cell Lymphoma

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions